Amyotrophic lateral sclerosis: Prolongation of life by noninvasive respiratory aids

Research output: Contribution to journalArticle

212 Citations (Scopus)

Abstract

Study objective: To describe prolongation of survival in patients with amyotrophic lateral sclerosis (ALS) by continuous noninvasive intermittent positive-pressure ventilation (NPPV) and mechanically assisted coughing (MAC) using oximetry as feedback. Setting: A retrospective review of ALS patients visiting one center from 1990 to 2000. Design: Patients were trained in mouthpiece and nasal NPPV when symptomatic for hypoventilation, and trained in MAC with oximetry feedback when assisted peak cough flow (PCF) levels decreased to < 270 L/min. Survival was considered to be prolonged when full-time NPPV was required with limited ventilator-free breathing tolerance. Results: Of 101 patients who met the criteria for access to NPPV and MAC, 15 have not yet used them, and 11 patients with severe bulbar muscle dysfunction died without ever successfully using them. Three patients used NPPV full-time, and oximetry and MAC episodically, but did not yet require ongoing NPPV. Eighteen used NPPV part-time for a mean (± SD) duration of 3.8 ± 4.1 months. Nineteen others underwent tracheotomy after 4.7 ± 4.5 months of receiving part-time NPPV. Sixteen patients used part-time NPPV for 17.5 ± 13.0 months (maximum, 25 months), then full-time NPPV for 14.1 ± 12.6 months (maximum, 40 months) before undergoing tracheotomy. Nineteen patients used part-time and full-time NPPV for 25.2 ± 19.8 months (maximum, 114 months) and 17.5 ± 13.3 months (maximum, 87 months), respectively, without undergoing tracheotomy. Ten of these NPPV users died once bulbar dysfunction became severe. Conclusion: We conclude that up to continuous use of NPPV, along with MAC when needed, can permit prolonged survival and delay the need for tracheotomy for a significant minority of ALS patients by > 1 year.

Original languageEnglish (US)
Pages (from-to)92-98
Number of pages7
JournalCHEST
Volume122
Issue number1
DOIs
StatePublished - Jan 1 2002

Fingerprint

Life Support Care
Amyotrophic Lateral Sclerosis
Intermittent Positive-Pressure Ventilation
Oximetry
Hypoventilation
Nose
Cough
Survival

All Science Journal Classification (ASJC) codes

  • Critical Care and Intensive Care Medicine
  • Cardiology and Cardiovascular Medicine
  • Pulmonary and Respiratory Medicine

Keywords

  • Amyotrophic lateral sclerosis
  • Exsufflation
  • Noninvasive mechanical ventilation
  • Survival
  • Tracheostomy

Cite this

@article{c048d3027d74468388ae0d44a4893876,
title = "Amyotrophic lateral sclerosis: Prolongation of life by noninvasive respiratory aids",
abstract = "Study objective: To describe prolongation of survival in patients with amyotrophic lateral sclerosis (ALS) by continuous noninvasive intermittent positive-pressure ventilation (NPPV) and mechanically assisted coughing (MAC) using oximetry as feedback. Setting: A retrospective review of ALS patients visiting one center from 1990 to 2000. Design: Patients were trained in mouthpiece and nasal NPPV when symptomatic for hypoventilation, and trained in MAC with oximetry feedback when assisted peak cough flow (PCF) levels decreased to < 270 L/min. Survival was considered to be prolonged when full-time NPPV was required with limited ventilator-free breathing tolerance. Results: Of 101 patients who met the criteria for access to NPPV and MAC, 15 have not yet used them, and 11 patients with severe bulbar muscle dysfunction died without ever successfully using them. Three patients used NPPV full-time, and oximetry and MAC episodically, but did not yet require ongoing NPPV. Eighteen used NPPV part-time for a mean (± SD) duration of 3.8 ± 4.1 months. Nineteen others underwent tracheotomy after 4.7 ± 4.5 months of receiving part-time NPPV. Sixteen patients used part-time NPPV for 17.5 ± 13.0 months (maximum, 25 months), then full-time NPPV for 14.1 ± 12.6 months (maximum, 40 months) before undergoing tracheotomy. Nineteen patients used part-time and full-time NPPV for 25.2 ± 19.8 months (maximum, 114 months) and 17.5 ± 13.3 months (maximum, 87 months), respectively, without undergoing tracheotomy. Ten of these NPPV users died once bulbar dysfunction became severe. Conclusion: We conclude that up to continuous use of NPPV, along with MAC when needed, can permit prolonged survival and delay the need for tracheotomy for a significant minority of ALS patients by > 1 year.",
keywords = "Amyotrophic lateral sclerosis, Exsufflation, Noninvasive mechanical ventilation, Survival, Tracheostomy",
author = "Bach, {John Robert}",
year = "2002",
month = "1",
day = "1",
doi = "https://doi.org/10.1378/chest.122.1.92",
language = "English (US)",
volume = "122",
pages = "92--98",
journal = "Chest",
issn = "0012-3692",
publisher = "American College of Chest Physicians",
number = "1",

}

Amyotrophic lateral sclerosis : Prolongation of life by noninvasive respiratory aids. / Bach, John Robert.

In: CHEST, Vol. 122, No. 1, 01.01.2002, p. 92-98.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Amyotrophic lateral sclerosis

T2 - Prolongation of life by noninvasive respiratory aids

AU - Bach, John Robert

PY - 2002/1/1

Y1 - 2002/1/1

N2 - Study objective: To describe prolongation of survival in patients with amyotrophic lateral sclerosis (ALS) by continuous noninvasive intermittent positive-pressure ventilation (NPPV) and mechanically assisted coughing (MAC) using oximetry as feedback. Setting: A retrospective review of ALS patients visiting one center from 1990 to 2000. Design: Patients were trained in mouthpiece and nasal NPPV when symptomatic for hypoventilation, and trained in MAC with oximetry feedback when assisted peak cough flow (PCF) levels decreased to < 270 L/min. Survival was considered to be prolonged when full-time NPPV was required with limited ventilator-free breathing tolerance. Results: Of 101 patients who met the criteria for access to NPPV and MAC, 15 have not yet used them, and 11 patients with severe bulbar muscle dysfunction died without ever successfully using them. Three patients used NPPV full-time, and oximetry and MAC episodically, but did not yet require ongoing NPPV. Eighteen used NPPV part-time for a mean (± SD) duration of 3.8 ± 4.1 months. Nineteen others underwent tracheotomy after 4.7 ± 4.5 months of receiving part-time NPPV. Sixteen patients used part-time NPPV for 17.5 ± 13.0 months (maximum, 25 months), then full-time NPPV for 14.1 ± 12.6 months (maximum, 40 months) before undergoing tracheotomy. Nineteen patients used part-time and full-time NPPV for 25.2 ± 19.8 months (maximum, 114 months) and 17.5 ± 13.3 months (maximum, 87 months), respectively, without undergoing tracheotomy. Ten of these NPPV users died once bulbar dysfunction became severe. Conclusion: We conclude that up to continuous use of NPPV, along with MAC when needed, can permit prolonged survival and delay the need for tracheotomy for a significant minority of ALS patients by > 1 year.

AB - Study objective: To describe prolongation of survival in patients with amyotrophic lateral sclerosis (ALS) by continuous noninvasive intermittent positive-pressure ventilation (NPPV) and mechanically assisted coughing (MAC) using oximetry as feedback. Setting: A retrospective review of ALS patients visiting one center from 1990 to 2000. Design: Patients were trained in mouthpiece and nasal NPPV when symptomatic for hypoventilation, and trained in MAC with oximetry feedback when assisted peak cough flow (PCF) levels decreased to < 270 L/min. Survival was considered to be prolonged when full-time NPPV was required with limited ventilator-free breathing tolerance. Results: Of 101 patients who met the criteria for access to NPPV and MAC, 15 have not yet used them, and 11 patients with severe bulbar muscle dysfunction died without ever successfully using them. Three patients used NPPV full-time, and oximetry and MAC episodically, but did not yet require ongoing NPPV. Eighteen used NPPV part-time for a mean (± SD) duration of 3.8 ± 4.1 months. Nineteen others underwent tracheotomy after 4.7 ± 4.5 months of receiving part-time NPPV. Sixteen patients used part-time NPPV for 17.5 ± 13.0 months (maximum, 25 months), then full-time NPPV for 14.1 ± 12.6 months (maximum, 40 months) before undergoing tracheotomy. Nineteen patients used part-time and full-time NPPV for 25.2 ± 19.8 months (maximum, 114 months) and 17.5 ± 13.3 months (maximum, 87 months), respectively, without undergoing tracheotomy. Ten of these NPPV users died once bulbar dysfunction became severe. Conclusion: We conclude that up to continuous use of NPPV, along with MAC when needed, can permit prolonged survival and delay the need for tracheotomy for a significant minority of ALS patients by > 1 year.

KW - Amyotrophic lateral sclerosis

KW - Exsufflation

KW - Noninvasive mechanical ventilation

KW - Survival

KW - Tracheostomy

UR - http://www.scopus.com/inward/record.url?scp=0036308999&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036308999&partnerID=8YFLogxK

U2 - https://doi.org/10.1378/chest.122.1.92

DO - https://doi.org/10.1378/chest.122.1.92

M3 - Article

C2 - 12114343

VL - 122

SP - 92

EP - 98

JO - Chest

JF - Chest

SN - 0012-3692

IS - 1

ER -